D&D Pharmatech Inc. Logo

D&D Pharmatech Inc.

Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.

347850 | KO

Overview

Corporate Details

ISIN(s):
KR7347850000
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 금토로80번길 27 (금토동, 텔레칩스) 4층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

D&D Pharmatech Inc. is a clinical-stage global biotechnology company focused on developing novel peptide-based therapies for metabolic and chronic diseases with high unmet medical needs. The company's core research centers on its portfolio of GLP-1 (Glucagon-like peptide-1) class drugs, targeting conditions such as obesity and MASH (Metabolic dysfunction-associated steatohepatitis). A key competency is its advanced oral peptide technology, which enables the creation of oral treatments in addition to injectable therapies. D&D Pharmatech operates a dual-center model, with a research team in Korea dedicated to peptide discovery and a clinical development team in the United States managing global trials and regulatory processes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-09-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-16 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-09 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.4 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 180.8 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.1 KB
2025-06-19 00:00
Regulatory News Service
기타경영사항(자율공시) (국책과제 선정(국가신약개발사업(R&D) (대사이상 관련 지방간염(MASH) 치료제 DD01 개…
Korean 7.9 KB
2025-06-17 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-06-16 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 Topline …
Korean 12.8 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-06-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-11 00:00
Capital/Financing Update
주요사항보고서(자본으로인정되는채무증권발행결정)
Korean 31.4 KB

Automate Your Workflow. Get a real-time feed of all D&D Pharmatech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for D&D Pharmatech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for D&D Pharmatech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL
Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.